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ABSTRACT 
The quest for chemical entities able to curb the action of the phosphoinositide 3-kinase, (PI3K)/protein kinase B 
(AKT) signaling pathways is evolving as a potential therapeutic strategy for the treatment and/or prevention of 
neurodegenerative disorders including Alzheimer’s disease (AD). In this study, the effects of a PI3K inhibitor, 
AS605240 on cognitive dysfunction and antioxidative defense parameters against intra-cerebroventricular-strep-
tozotocin (ICV-STZ)-induced rat model of sporadic AD was evaluated. ICV administration of a single dose of 
STZ (3 mg/kg) was performed to induce behavioral and biochemical changes in rats using the stereotaxic tech-
nique. Animals were administered with varying doses of AS605240 (5, 10 and 15 mg/kg) orally, 1 h before ICV-
STZ on day 1 and continued once daily for four weeks. The behavioral parameters (passive avoidance and Morris 
water maze), antioxidative defense parameters, amyloid-beta (Aβ) protein expression by Western blotting and 
immunostaining technique were estimated in brain tissue. AS605240 dose-dependently and significantly (p < 0.05 
and p < 0.01 and p < 0.001) improved ICV-STZ-induced cognitive impairment and attenuated the altered antiox-
idative related parameters including superoxide dismutase, lipid peroxidation, glutathione and nitrite levels. Fur-
ther, the increased Aβ protein expression levels in brain tissue were markedly restored with AS605240 treatment. 
In conclusion, our study demonstrated that AS605240 exhibited immense potential in attenuating STZ-induced 
sporadic AD features in rats and may be developed as a therapeutic agent in the treatment and management of 
sporadic AD. 
 
Keywords: Alzheimer’s disease, AS605240, PI3K inhibitor, streptozotocin, intra-cerebroventricular injection, ox-
idative stress, cognition 
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INTRODUCTION 
Alzheimer’s disease (AD) is the principal 
cause of dementia in people over 65 years old, 
distressing millions of patients worldwide. 
Since its pervasiveness increases significantly 
with life expectancy the social impact of AD 
will be appalling if no effective therapy is de-
veloped in a near future (Brookmeyer et al., 
1998). The neuropathological hallmarks of 
AD include intracellular neurofibrillary tan-
gles of hyper-phosphorylated tau, extracellu-
lar senile plaques and vascular deposits 
mainly composed of amyloid beta (Aβ) pep-
tide, and selective synaptic and neuronal loss, 
particularly in the hippocampus and cerebral 
cortex (DeKosk, 2003; Selkoe, 2001; Masliah 
et al., 1994). Accordingly, to the amyloid cas-
cade hypothesis, abnormal deposition of Aβ 
is the central mechanism underlying patho-
logical processes in AD (Hardy and Selkoe, 
2002). This notion is supported by the fact 
that all genetic mutations associated with fa-
milial AD increase the production of Aβ 
which is generated from the amyloid-β 
protein precursor (APP) through the cleavage 
by β- and γ-secretases (Tanzi and Bertram, 
2005; Zhang et al., 2010). Currently existing 
classes of medication for the treatment of Alz-
heimer’s disease (AD), namely acetylcholin-
esterase inhibitors such as tacrine, rivastig-
mine, and galantamine and the N-methyl-D-
aspartate receptor antagonist memantine have 
limited clinical benefits in terms of enhanced 
cognition and eventually do not prevent the 
disease progression (DeKosk, 2003; Casey et 
al., 2010; Stuchbury and Münch, 2005). 
Therefore, exploring novel mechanistic strat-
egies that prevent the pathological conditions 
of AD are quite necessary. 
Mounting evidence suggests that the 
phosphoinositide 3-kinase, (PI3K)/protein ki-
nase B (AKT) signaling pathway is directly 
impacted by Aβ exposure and is altered in AD 
brains. Aβ oligomers have been shown to 
modulate expression and density of insulin re-
ceptors that mediate growth and cell survival 
through the modulation of PI3K/Akt pathway 
(Zhao et al., 2008). Further, several experi-
ments on animal models revealed a marked 
increase in the phosphorylated Akt levels 
such as mammalian target of rapamycin 
(mTOR) and decreased cell-cycle inhibitors 
(p27kip1) in AD temporal cortex compared 
with control groups (Griffin et al., 2005). 
These studies suggest that the components of 
insulin receptor and PI3K-Akt-mTOR path-
way are affected in AD and correlate with al-
tered cell cycle related events. Aβ oligomers 
alter the PI3K/Akt/mTOR pathway within 
neurons, and in turn promotes the expression 
of cell cycle proteins and the induction of neu-
ronal cell cycle events which eventually leads 
to neuronal degeneration. In light of such re-
ports, inhibition or regulation of PI3K/Akt 
signaling pathway might be a potential thera-
peutic strategy in ameliorating AD-like spo-
radic dementia.  
AS605240 is a potent member of a new 
class of PI3Kγ-selective inhibitors with 
IC50 = 8 nM, and displaying over 30-fold 
more selectivity for PI3Kδ/β and 7.5-fold se-
lectivity over PI3Kα in cell-free assays 
(Camps et al., 2005; Cushing et al., 2012). 
Pharmacologically, AS605240 is orally active 
and ATP-competitive (Peng et al., 2010). Ear-
lier studies showed that AS605240 attenuated 
the joint inflammation progression in lym-
phocyte-dependent and independent rheuma-
toid arthritis mouse models (Camps et al., 
2005). AS605240 also demonstrated a promi-
nent role in regulating neuroblastoma tumors, 
autoimmune diabetes, autoimmune myocar-
ditis, prevented bleomycin-induced pulmo-
nary fibrosis, ameliorated concanavalin A-in-
duced hepatic injury and dextran sodium sul-
fate-induced colitis in mice, prevented isopro-
terenol-induced hypertrophy and cardiac fi-
brosis, blocked the glomerulonephritis and in-
creased the life span in various experimental 
animal models (Spitzenberg et al., 2010; Azzi 
et al., 2012; Barber et al., 2005; Wang et al., 
2009; Jin et al., 2009; Peng et al., 2010; Song 
et al., 2011; Wei et al., 2010). However, the 
protective effects of AS605240 against neu-
rotoxicity-induced experimental models of 
AD-like sporadic dementia was not studied. 
Earlier reports indicated that a single in-
tra-cerebroventricular (ICV) injection of 
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streptozotocin (STZ; 3 mg/kg) is the most ap-
propriate for induction of long term cognitive 
impairment, which can be used as a model of 
sporadic AD in experimental animals 
(Prickaerts et al., 1999; Ramezani et al., 2016). 
ICV-STZ experimental model exhibited neu-
rochemical changes including behavioral and 
histological which are similar to human AD 
pathology (Dhull et al., 2012; Ponce-Lopez et 
al., 2011). Further, ICV-STZ model displayed 
neuroinflammation, reproduces amyloid pa-
thologies as well as AD-like cognitive deficits 
(Correia et al., 2011; Chen et al., 2013; Nitsch 
and Hoyer, 1991; Kraska et al., 2012; Mehla 
et al., 2013).  
In light of such reports, in the present 
study we aimed to investigate the effect of 
AS605240 on behavioral and cognitive im-
pairments in ICV-STZ-induced rat model of 
sporadic AD. Further, the therapeutic benefits 
of AS605240 on antioxidative defense param-
eters and Aβ protein expression was also eval-
uated in rat brain tissues. 
 
MATERIALS AND METHODS 
Chemicals 
AS605240 (5-quinoxalin-6-ylmethylene-
thiazolidine-2,4-dione (98 % pure, Figure 
1A), glutathione (GSH), STZ, 5,5´-Dithiobis-
2-nitrobenzoic acid (DTNB), 2-thiobarbituric 
acid (TBA), bovine serum albumin (BSA), 
and phosphate buffered saline (PBS), were 
purchased from Sigma (St. Louis, USA). An-
tibodies for Western blotting (WB) and im-
munohistochemistry were procured from 
Invitrogen, Camarillo, CA, USA. All the drug 
solutions were freshly prepared before admin-
istration. 
 
Animals  
Wistar rats of either sex weighing 150-
200 g (age, 8-12 weeks) were used in this 
study. Animals were housed in the Central 
Animal Facility of Vishnu Institute of Phar-
maceutical Education and Research, under a 
12 h light/dark cycle and specific pathogen 
free conditions with food and water ad libi-
tum. Experiments were conducted according 
to the “Purpose of Control and Supervision of 
Experiments on Animals (CPCSEA) guide-
lines” and our Institutional Animal Care and 
Use Committee (No: 1358/ac/10/CPCSEA). 
 
 
 
Figure 1: A: Structure and chemical name of AS605240. B: The experimental design, treatment 
schedule and intervals for estimation of various parameters. ICV-STZ=intra-cerebroventricular- 
streptozotocin, PA=Passive avoidance, MWM=Morris water maze, and SAC=sacrificed. 
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Surgery and ICV-STZ administration 
ICV injection of STZ was performed as 
previously described (Giacobini, 2006). 
Briefly, rats were anesthetized with intraperi-
toneally (i.p.) injection of ketamine hydro-
chloride (70 mg/kg, i.p.) immediately fol-
lowed by diazepam (4 mg/kg, i.p.). The ani-
mal was laid on surgery board, and the head 
was positioned straight, hair was trimmed, 
and a midline sagittal incision was made in 
the scalp. Two holes were drilled in the skull 
on both sides over the lateral ventricles using 
the following coordinates: 0.8 mm posterior 
to the bregma, 1.5 mm lateral to the sagittal 
suture, and 3.6 mm beneath the surface of the 
brain. Through a skull hole, a 28-gauge Ham-
ilton syringe of 10 μl attached to a micro-in-
jector unit and piston of the syringe was low-
ered manually into the lateral ventricle. The 
lesioned groups received bilateral ICV injec-
tion of STZ (3 mg/kg b.w) in artificial cere-
brospinal fluid (ACSF) as described in earlier 
reports (Paxinos and Watson, 1986). Similar 
surgical procedures were followed for control 
group with ACSF injections instead of STZ. 
During the operation and recovery, rats were 
held on a warm pad. For recovery, the rats 
were housed singly until their behavior re-
turned to normal. 
 
Animal groups and drug treatments 
After acclimatization for one week, ani-
mals were randomly separated into seven 
groups (n=12). The control Group I received 
a single ICV infusion of ACSF. Group II was 
infused with a single dose of STZ on day 1 (3 
mg/kg, ICV). Group III, IV and V were in-
fused with a single dose of STZ (3 mg/kg, 
ICV) on day 1 and immediately after STZ in-
fusion were treated once a day orally (p.o.) 
with AS605240 (5, 15 and 25 mg/kg/day, re-
spectively) for 21 days. Group VI was infused 
with a single dose of STZ (3 mg/kg, ICV) on 
day 1 and immediately after STZ infusion was 
treated once a day orally (p.o.) with a standard 
drug, donepezil (0.1 mg/kg; p.o.) for 21 days. 
AS605240 and donepezil were dissolved in 
vehicle (PBS) and the solution was adjusted 
to 10 ml/kg of body weight. Animals were 
subjected to the behavioral and biochemical 
tests after the fourth week of STZ or ACSF 
infusions. 
 
Behavioral studies 
Behavioral tests started fourth week after 
ICV-STZ infusion and final administration of 
AS605240 or donepezil. The experiments 
were executed between 9:00 am and 4:00 pm 
in the laboratory at standard optimal condi-
tions. All the tests were performed and ana-
lyzed by a researcher blind to the experiment. 
 
Passive avoidance test 
On days 22 and 23, the rats were screened 
for memory retention deficits using a passive 
avoidance test (Raghavendra and Kulkarni, 
2001). The apparatus consisted of a two-com-
partment dark/light shuttle box with a behead 
door splitting the compartments. The dark 
compartment had a stainless steel shock grid 
floor. During the acquisition trial, each rat 
was positioned in the light chamber. After a 
60 s habituation period, the guillotine door 
was unlocked, and the initial latency of the 
animals to get into the dark chamber was rec-
orded. Rats with an initial latency time of 
more than 60 s were disqualified from further 
experiments. Immediately after the rat had got 
into the dark chamber, the guillotine door was 
locked and an electric foot shock (75 V; 
0.2 mA, 50 Hz) was treated to the floor grid 
with a stimulator for 3 s. Five seconds later, 
the rat was taken from the dark chamber and 
returned to home cage. After 24 h, the reten-
tion latency time was measured in the same 
way as in the acquisition trial, but the foot 
shock was not given and the latency time was 
recorded to a maximum of 600 s. Short laten-
cies indicate poorer retention. 
 
Morris water maze (MWM) test 
After completion of passive avoidance 
test, spatial learning and memory of the ani-
mals were tested in a Morris water maze 
(Morris, 1984). It contained of circular water 
tank (130 cm diameter, 62 cm height) filled 
40 cm with water (25 ± 2 °C). A non-toxic 
paint was used to render the water cloudy. 
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The pool was divided into four equal quad-
rants, labeled North, South, East, and West. 
An escape platform (10 cm in diameter) was 
hidden 2 cm underneath the surface of the wa-
ter at a fixed location in one of the quadrants. 
The platform is placed in the same quadrant 
during the complete experiment. Before the 
training is initiated, rats were permitted to 
swim freely in the pool for 60 s with the plat-
form. After climbing the platform, the animal 
remained there for 30 s before the instigation 
of the next trial. If the rat failed to detect and 
reach the escape platform within the maxi-
mum allowed time of 60 s, it was gently posi-
tioned on the platform and permitted to re-
main there for the same interval of time. The 
time for each platform (latency in seconds) 
was noted. Twenty-four hours after the acqui-
sition phase, a probe test was led by removing 
the platform. Rats were permitted to swim 
freely in the pool for 60 s. The time spent in 
the target quadrant, which had previously 
contained the hidden platform, was noted. 
The time spent in the target quadrant indicates 
the degree of memory consolidation which 
had taken place after learning. 
 
Biochemical analysis 
Tissue preparations 
Twenty-four hours after the MWM tests, 
animals were euthanized under deep anesthe-
sia, and their brains were extracted quickly 
and kept over a glass plate on ice. Hippocam-
pus and cerebral cortex were dissected care-
fully as described previously (Paxinos and 
Watson, 1986). Six brains were dissected to 
half along the midline, and frozen on dry ice 
immediately. One hemisphere was used for 
WB where in the tissues were homogenized 
in lysis buffer and the other hemisphere were 
separately homogenized in 10 mM tris-buffer 
(pH 7.4) containing protease inhibitors. The 
homogenate was centrifuged at 800 ×g for 5 
min at 4 °C to separate the nuclear debris and 
used for estimation of lipid peroxidation 
(LPO). The supernatant was further centri-
fuged at 10,000 ×g for 20 min at 4 °C to get 
the post mitochondrial supernatant (PMS), 
which was used for other biochemical assays. 
The brains of other six rats in each group, af-
ter transcardial perfusion with saline followed 
by 4 % paraformaldehyde, were fixed in 
3.7 % formaldehyde in PBS 1X solution. The 
brains were embedded in paraffin and cut into 
thin section of 5 µm each for immunohisto-
chemistry analysis. 
Measurement of LPO 
The estimation of thiobarbituric acid-re-
active species (TBARS), an index of LPO in 
the brain, was performed as reported previ-
ously (Ohkawa et al., 1979). Briefly, 0.1 ml 
of supernatant was incubated with 0.5 ml 
Tris-HCl (0.1 M, pH 7.4) for 2 h. To this, 1 
ml of trichloroacetic acid (10 %, w/v) was 
added and centrifuged at 1,000×g for 10 min. 
To 1 ml supernatant, 1 ml (0.67 %, w/v) thio-
barbituric acid (TBA) was added and kept in 
the boiling water bath for 10 min, cooled, and 
added 1 ml distilled water. The amount of li-
pid peroxidation products was measured by 
reaction with TBA at 532 nM using the T60 
UV/VIS spectrophotometer (PG Instruments 
Limited, India). 
Effect on brain nitrite level 
The brain nitrite levels in supernatant was 
determined using a colorimetric assay as de-
scribed previously (Green et al., 1982). 
Briefly, equal volumes of supernatant and 
Greiss reagent were mixed, the mixture was 
incubated for 10 min at room temperature in 
the dark, and the absorbance at 540 nm was 
determined with T60 UV/VIS spectrophoto-
meter (PG Instruments Limited, India). The 
concentration of nitrite was expressed as mi-
cromoles per milligram protein. 
Effect on brain GSH level 
GSH content in the brain was estimated 
according to the method described by Ellman 
(1959). Briefly, 1 ml supernatant was precip-
itated with 1 ml of 4 % sulfosalicylic acid at 
4 °C for 1 h. The samples were centrifuged at 
1,200×g for 15 min at 4 °C. To 1 ml of this 
supernatant, 2.7 ml of phosphate buffer (0.1 
M, pH 8) and 0.2 ml of 5,5-dithio-bis (2-ni-
trobenzoic acid) were added. The absorbance 
of the yellow color developed was measured 
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at 412 nm using T60 UV/VIS spectrophotom-
eter (PG Instruments Limited, India). 
Effect on brain superoxide dismutase (SOD) 
activity 
SOD activity was determined according 
to the previous method (Beauchamp and Fri-
dovich, 1971). One unit (U) of SOD activity 
is defined as the amount of enzyme required 
to inhibit the rate of nitro blue tetrazolium 
(NBT) reduction by 50 %. The absorbance of 
the reaction mixture was measured at 550 nm 
using T60 UV/VIS spectrophotometer (PG 
Instruments Limited, India) and enzymatic 
activity was expressed as U/mg protein. 
 
Western blot analysis  
Western blot analysis was performed ac-
cording to the manufacturer's protocols (Invi-
trogen, Carlsbad, CA). The protein concentra-
tions of the homogenized brain sections were 
measured using the Bradford protein assay 
(Bio-Rad Laboratories, Hercules, CA, USA). 
Proteins were resolved by 4-20 % SDS-
PAGE gel electrophoresis and electro trans-
ferred onto nitrocellulose membranes. After 
blocking with 5 % non-fat milk, the mem-
branes were subjected to immunoblot analysis 
by incubation overnight with primary anti-
bodies of rabbit polyclonal anti-APP (catalog 
number: 51-2700; 1:1000 dilution; Invitro-
gen, Camarillo, CA, USA) and anti-β-tubulin 
(Invitrogen, Camarillo, CA, USA, catalog 
number: 32-2600; dilution: dilution 1:4000) 
to normalize for the amount of protein loaded. 
Blots were washed with PBS and detected uti-
lizing goat anti-rabbit or goat anti-mouse sec-
ondary antibody conjugated with horseradish 
peroxidase (dilution, 1: 100,000; A32735; 
Invitrogen, Camarillo, CA, USA). Protein 
bands were visualized using chemilumines-
cence reagent (ECL Plus) and exposed on X-
ray film (Kodak, Rochester, NY, USA). The 
densitometric analysis of protein bands were 
imaged with alpha imager gel documentation 
system (FluorChem E; Cell Biosciences, 
USA) with β-tubulin as a loading control. 
 
Immunocytochemistry  
For immunohistochemistry, brain sec-
tions were deparaffinized, washed (3-10 min) 
with 0.1 M phosphate buffered saline (PBS) 
(pH 7.4) and incubated in blocking solution 
(PBS containing 0.3 % Triton X-100, 0.1 % 
BSA, and 2 % normal goat serum) for 2 h at 
room temperature. Primary and secondary an-
tibodies were diluted in blocking solution. 
Following blocking, sections were incubated 
with polyclonal rabbit antibody to β-amyloid 
42 (1:1000, Invitrogen) overnight at 4 °C with 
gentle shaking. After the overnight incuba-
tion, sections are rinsed with PBS twice, and 
the immunoreactivity was detected by incu-
bating for 1 h in horseradish peroxidase-con-
jugated goat anti-rabbit IgG (Invitrogen, 1: 
1,000). After incubation the sections were 
washed three times with PBS and 100 µl 3,3′-
diaminobenzidine (DAB) was added as a 
color reagent solution to the sections, and the 
reaction was observed under a microscope. 
The sections were counterstained with 0.1 % 
Cresyl violet (Nissl stain). Sections were de-
hydrated with gradient alcohol and sealed 
with neutral gum. The appearance of brown 
DAB reaction products was identified as pos-
itive staining. 
 
Statistical analysis 
Data are expressed as means ± standard 
error of the mean (S.E.M.). The behavioral 
and biochemical data were analyzed by one-
way analysis of variance (ANOVA) followed 
by Bonferroni’s post hoc test using GraphPad 
Prism 5 software (GraphPad Software Inc., 
USA). In all experiments, a value of p < 0.05 
was considered as statistically significant. 
 
RESULTS 
Effect of AS605240 on memory retention 
deficit in passive avoidance test  
To evaluate the effect of AS605240 on 
memory performance in passive avoidance 
task, the acquisition latency (AL) and reten-
tion latency (RL) in ICV-STZ rats was stud-
ied (Figure 2). On day 22, the AL values 
showed no significant differences across the 
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groups tested. However, the RL in STZ-in-
duced rat group on day 23 was significantly 
(p < 0.001) lower (220 ± 29 s) than those rec-
orded for the control group (504 ± 33 s). The 
RL times in AS605240 treated groups im-
proved significantly (p < 0.05 and p < 0.001) 
in a dose-dependent manner in antagonizing 
memory deficits induced by ICV-STZ (5 
mg/kg, 320 ± 37; 15 mg/kg, 356 ± 27s; 25 
mg/kg, 402 ± 25s). The standard donepezil 
treated group also showed significant (p < 
0.001) effect compared with ICV-STZ alone 
treated group and the values are comparable 
with AS605240 treated at 25 mg/kg dose (p < 
0.01, 421 ± 38s).  
 
Effects of AS605240 on escape latency in 
rats by MWM test 
The effect of AS605240 on escape latency 
in ICV-STZ-induced rats was evaluated by 
MWM task (Figure 3A). After 5 days of train-
ing, the escape latency to reach the submerged 
platform decreased in all groups. From day 2 
to day 5, the average latency to locate the hid-
den platform in STZ group was significantly 
(p < 0.001) increased reaching maximum on 
fifth day of training trials when compared 
with the control group. This indicates a poorer 
learning and memory performance in STZ 
treated groups. Treatment with AS605240 at 
indicated doses (5, 15 and 25 mg/kg) signifi-
cantly (p < 0.01 and p < 0.001) decreased es-
cape latency compared with the STZ group. 
The standard donepezil treated group showed 
similar effects as compared with 25 mg/kg of 
AS605240 treated group (p < 0.001). Similar 
effects were observed in the spatial probe test 
with the platform removed. STZ treated rats 
had a significantly (p < 0.001) decreased 
amount of time spent in the target quadrant 
than the control group rats. However, the 
amount of time spent in the target quadrant by 
the rats in the AS605240 treated groups was 
much longer than that in the STZ group (Fig-
ure 3B, p < 0.01 and p < 0.001), supporting a 
protective effect on learning and memory. 
 
Effect of AS605240 on LPO levels 
The effect of AS605240 on brain LPO 
levels in ICV-STZ-induced rats was shown in 
Figure 4A. ICV-STZ-administered rats had 
significantly increased level of TBARS in 
brain in comparison to control animals (p < 
0.001). Administration of AS605240 (5, 15 
and 25 mg/kg) prevented ICV-STZ induced 
increase in brain TBARS level significantly 
(p < 0.05, p< 0.01 and p < 0.001) in a dose- 
 
 
 
Figure 2: Effect of AS605240 on memory performance passive avoidance test in ICV-STZ rats. 
Latency time was recorded to a maximum of 600 s. Values are expressed as means ± S.E.M. (n=12). 
STZ-induced rats showed shorter retention latency compared with control group (#p < 0.001 vs control 
group). AS605240 (5, 15 and 25 mg/kg) and donepezil treatment in ICV-STZ-induced groups dose-
dependently and significantly increased the retention latencies compared with STZ alone treated group 
(*p < 0.05, **p < 0.01 and ***p < 0,001, respectively). STZ: Streptozotocin 
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Figure 3: Effect of AS605240 on memory performance in Morris water maze (MWM) task in ICV-
STZ-induced rats. A: Supplementation on escape latency to hit the target platform in MWM test in ICV-
STZ rats on days 16 to 20. Swimming times of four trials per day for 5 days to each group are shown. 
Values are expressed as means ± S.E.M. (n=12). Average escape latency time (days 2-5) to find hidden 
platform was significantly prolonged in the ICV-STZ group compared with the control group (#p < 0.001 
vs control group). AS605240 (5, 15 and 25 mg/kg) and donepezil treatment in ICV-STZ-induced groups 
dose-dependently and significantly reversed the ICV-STZ-induced learning deficit compared with STZ 
alone treated group (**p < 0.01 and ***p < 0.001, respectively). B: Percentage of time spent in the target 
quadrant in ICV-STZ rats. Values are expressed as means ± S.E.M. (n=12). The percentage of time 
spent in the target quadrant was significantly lesser in the ICV-STZ group compared with the control 
group (#p < 0.001). AS605240 (5, 15 and 25 mg/kg) and donepezil treatment in ICV-STZ-induced groups 
significantly attenuated STZ-induced memory deficits when compared with the STZ alone treated group 
(*P<0.05 L vs. control group; **p < 0.01 and ***p < 0.001 respectively). STZ: Streptozotocin 
 
 
dependent fashion. The standard donepezil 
(0.1 mg/kg) treated group also decreased the 
TBARS level and was similar to AS605240 
treated at 25 mg/kg treated group in the brains 
of ICV-STZ-administered rats (p < 0.001). 
 
Effect of AS605240 on nitrite levels 
The effect of AS605240 on brain nitrite 
levels in ICV-STZ-induced rats was shown in 
Figure 4B. ICV-STZ-administered rats signif-
icantly (p < 0.001) increased brain nitrite level 
in comparison to control animals. Admin-
istration of AS605240 (5,15 and 25 mg/kg) in 
ICV-STZ-induced animals significantly (p < 
0.05, p< 0.01 and p < 0.001) reduced the brain 
nitrite level as compared to ICV-STZ-admin-
istered rats and the effects were dose-depend-
ent. Similar results were observed in standard 
donepezil treated group and the effect was 
same as AS605240 treated at 25 mg/kg dose 
in ICV-STZ-treated rats (p < 0.001). 
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Figure 4: Effect of AS605240 on brain lipidpe-
roxidation (LPO) and nitrite levels in ICV-STZ-
induced rats. ICV-STZ treated rats showed a sig-
nificant increase in brain TBARS (A) and nitrite 
(B) when compared to the control group. Admin-
istration of AS605240 (5,15 and 25 mg/kg) and 
donepezil (0.1 mg/kg; p.o.) prevented ICV-STZ in-
duced increase in brain TBARS and nitrate levels 
dose-dependently and significantly when com-
pared with STZ alone treated groups. The results 
are presented relative to control and the values 
are expressed as means ± S.E.M. (n=12). #p < 
0.001 when compared with control group and *p < 
0.05, **p < 0.01 and ***p < 0,001, respectively when 
compared with STZ alone treated group. STZ: 
Streptozotocin, TBARS: Thiobarbituric acid reac-
tive substances 
 
Effect of AS605240 on GSH levels 
The effect of AS605240 on brain GSH 
levels in ICV-STZ-induced rats was shown in 
Figure 5A. ICV-STZ administered rats 
showed significantly decreased level of GSH 
in the brain (p < 0.001). Treatment with 
AS605240 (5, 15 and 25 mg/kg) improved the 
depleted GSH level in brain as compared to 
STZ-treated rats significantly and concentra-
tion-dependently (p < 0.001). The standard 
donepezil (0.1 mg/kg) treated group also at-
tenuated the altered levels of GSH and the ef-
fect was similar to AS605240 treated at 25 
mg/kg dose (p < 0.001). 
Effect of AS605240 on SOD levels 
The effect of AS605240 on SOD levels in 
ICV-STZ-induced rats was shown in Figure 
5B. ICV-STZ-administered rats showed sig-
nificantly decreased activity of SOD in the 
brain in comparison to control animals (p < 
0.001). However, administration of 
AS605240 (5, 15 and 25 mg/kg) significantly 
and dose-dependently attenuated the reduc-
tion in SOD activity as compared to ICV-STZ 
alone treated rats (p < 0.05, p < 0.01 and p < 
0.001, respectively). The standard donepezil 
(0.1 mg/kg) treated group also attenuated the 
altered levels of SOD and the effect was sim-
ilar to AS605240 treated at 25 mg/kg dose (p 
< 0.001). 
 
Figure 5: Effect of AS605240 on glutathione 
(GSH) and super oxide dismutase (SOD) in 
ICV-STZ-induced rats. ICV-STZ treated rats 
showed a significant decrease in GSH (A) and 
SOD (B) levels when compared to the control 
group. Administration of AS605240 (5, 15 and 25 
mg/kg) and donepezil (0.1 mg/kg; p.o.) prevented 
ICV-STZ induced decrease in GSH and SOD lev-
els significantly in a dose-dependent fashion 
when compared with STZ alone treated groups. 
The results are presented relative to control and 
the values are expressed as means ± S.E.M. 
(n=12). #p < 0.001 when compared with control 
group and *p < 0.05, **p < 0.01 and ***p < 0,001, 
respectively when compared with STZ alone 
treated group. STZ: Streptozotocin. GSH: Gluta-
thione, SOD: Superoxide dismutase 
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Effects of AS605240 on APP expression 
To determine whether AS605240 de-
creased Aβ levels by changing APP pro-
cessing, we analyzed the expression of APP 
using WB analysis with anti-APP antibody 
(Figure 6A). The expression of APP was 
markedly increased in STZ-treated rats com-
pared with the control group. However, in 
AS605240-treated rats (15 and 25 mg/kg), the 
APP expression was lowered dose-depend-
ently (p < 0.05 at 15 mg/kg and p < 0.01 at 25 
mg/kg) when compared with STZ-treated rats 
and similar effects were observed with the 
standard donepezil treatment (p < 0.01). Alt-
hough the low dose of (5 mg/kg) of 
AS605240 treatment decreased the expres-
sion of APP when compared with STZ-in-
duced group, the results were not statistically 
significant (Figure 6B).  
 
 
Figure 6: Effect of AS605240 on amyloid β pre-
cursor protein (APP) production in ICV-STZ-in-
duced rat brain homogenates. APP protein lev-
els in rat brain extracts were determined by im-
munoblot analysis (A) and quantified by image 
analysis (B). Equal loading of proteins was illus-
trated by β-tubulin bands. Values are expressed 
as means ± S.E.M. (n=12). #p < 0.001 when com-
pared with control group and *p < 0.05, **p < 0.01 
and ***p < 0,001, respectively when compared with 
STZ alone treated group. APP: Amyloid β precur-
sor protein, STZ: Streptozotocin 
 
 
Effect of AS605240 Immunohistostaining 
of Aβ  
To determine the accumulation of Aβ in 
ICV-STZ-induced rat brain tissue, immuno-
histostaining of Aβ was performed (Figure 7). 
Immunohistostaining using the polyclonal 
rabbit antibody to β-amyloid 42, which recog-
nizes the Aβ peptide signal revealed that STZ 
injected rats had strong reaction with Aβ anti-
body with marked brown reaction products 
(DAB) in hippocampal areas compared with 
the control group which showed week reac-
tion (Figure 7a-7b). In contrast, in AS605240 
(5, 15 and 25 mg/kg) treated ICV-STZ-in-
duced rats the Aβ peptide signal was de-
creased with increasing doses (Figure 7c-7e). 
These results suggested that the AS605240 
may promote clearance of soluble intracellu-
lar Aβ deposits. The standard donepezil (0.1 
mg/kg) treated group also decreased the Aβ 
signal and the effect was similar to AS605240 
treated at 25 mg/kg dose (Figure 7f). 
 
Figure 7: Effect of AS605240 on immunohisto-
staining in ICV-STZ-induced brain sections of 
rats. Immunoreactive signal of amyloid-β visual-
ized by polyclonal rabbit antibody to β-amyloid 42. 
(a): Control group, (b): ICV-STZ-induced group, 
(c): AS605240 (5 mg/kg) treated group, (d): 
AS605240 (15 mg/kg) treated group, (e): 
AS605240 (25 mg/kg) treated group, and (f): 
Donepezil (0.1 mg/kg) treated group. The brown 
reaction product (DAB) shown in arrows could be 
seen markedly in STZ alone treated group (b) and 
weak staining in AS605240 and donepezil treated 
groups. Nissl counterstain. Scale bars 100 µm. 
Magnification 200X. STZ: Streptozotocin 
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DISCUSSION 
The present study was focused on the pro-
tective effects of AS605240, a potential PI3K 
inhibitor on cognitive deficits, antioxidative 
defense parameters and APP expression in 
ICV-STZ induced sporadic AD model in rats. 
It is well documented that a single dose of 
ICV-STZ (3 mg/kg) induced rats showed sig-
nificant impairments in memory and learning 
in behavioral test and further altered the anti-
oxidative defense markers and increased the 
protein expression of APP (Fanoudi et al., 
2018). In agreement with the published data, 
in the present study ICV-STZ induced patho-
logical alterations simulated sporadic AD-
like pathology by altering memory and learn-
ing, oxidative stress and as well as increased 
expression of APP. However, treatment with 
AS605240 (5, 15 and 25 mg/kg) significantly 
and concentration-dependently ameliorated 
the cognitive impairments induced by ICV-
STZ and further ameliorated the ICV-STZ-in-
duced alterations in biochemical parameters 
including antioxidative defense parameters 
and the protein expression of APP. 
Several studies on AS605240 suggested a 
range of concentrations varying from as low 
as 5 mg/kg to as high as 1000 mg/kg for 40-
60 days is safe and non-toxic in experimental 
animals (Salkovic-Petrisic et al., 2011; Passos 
et al., 2010). Oral administration of 
AS605240 (5-50 mg/kg) has been shown to 
be pharmacologically effective in several an-
imal disease models, and is able to cross the 
blood brain barrier (BBB) in the normal brain 
and damaged BBB in the ischemic brain (Jin 
et al., 2019). Further, reports also revealed 
that AS605240 (10 mg/kg) exhibited anti-in-
flammatory effects by significantly reducing 
brain water content within peri-resection 
brain tissues and improved the neurological 
performance in surgical brain injury animal 
models (Huang et al., 2015). Based on these 
reports, in the present study the concentra-
tions of 5, 15 and 25 mg/kg body weight of 
AS605240 were employed. Notably, no obvi-
ous side effects or toxic reactions were ob-
served in the groups treated with indicated 
concentrations of AS605240.  
In behavioral studies, ICV-STZ induced 
group showed impairment in learning and 
memory by reduction in latency time to enter 
the dark side of the chamber in passive avoid-
ance task. Further, in MWM behavior task, 
ICV-STZ-induced group showed an increase 
in the escape latency time and reduction in the 
percentage of time spent in the target quad-
rant. The results are consistent with previous 
reported studies indicating cognitive deficits 
in ICV-STZ-induced rats (Javed et al., 2012; 
Mansouri et al., 2013; Chen et al., 2016). 
However, treatment with AS605240 reversed 
these changes in both the behavioral tasks 
tested suggesting improved learning and 
memory abilities. 
Depletion in oxidative defense mecha-
nisms via free radical attack initiates a cas-
cade of debilitating events that progress brain 
aging and AD symptoms (Christen, 2000; Liu 
et al., 2003; Barnham et al., 2004). LPO, and 
imbalance in the antioxidative defense mark-
ers including the GSH, SOD and nitrite in the 
brain increases the free radical mediated pro-
gression of AD pathogenesis and memory im-
pairments (Sultana et al., 2013; Saharan and 
Mandal, 2014; Wink et al., 2001; Javed et al., 
2012; Susswein et al., 2004). Earlier reports 
indicated that ICV-STZ infusion enhanced 
the LPO and nitrite levels and decreased the 
antioxidant marker status of GSH and SOD in 
experimental animals (Ishrat et al., 2009; 
Mehla et al., 2012). In agreement with the 
previous reports, in the present study, the al-
tered levels of LPO, GSH, SOD and nitrite 
levels were attenuated in brain tissues demon-
strating antioxidant defense mechanism of 
AS605240. 
It was well documented that Aβ accumu-
lation as a key role in the mechanism of neu-
ron damage and cognitive dysfunction and 
formation of amyloid plaques is considered as 
one of the main hallmarks of AD (Harrington 
et al., 2015). Earlier studies indicated that 
ICV-STZ induced rats showed a decrease in 
brain weight, cognitive decline, a significant 
increase in hippocampal Aβ with increased 
expression of APP (Correia et al., 2013; Lind-
berg et al., 2012). Therefore, in the present 
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study, the expression of APP was evaluated 
using WB and the deposition of Aβ was visu-
alized immunohistochemically. As expected, 
WB analysis in ICV-STZ injected rat brain 
tissues clearly increased the expression of 
APP and treatment with AS605240 showed a 
reduction of APP expression. Further, immu-
noreactive signal of Aβ showed marked ap-
pearance of the brown reaction product (DAB) 
in ICV-STZ-induced group and AS605240 
treated groups (5, 15 and 25 mg/kg) showed 
dose-dependent decrease in the reaction prod-
ucts with weak Aβ signal with increased con-
centrations of AS605240.  
In the present study, donepezil was used 
as a standard as it has been well reported to 
rescue learning and memory related behav-
ioral impairments, attenuate the altered anti-
oxidative defense parameters and reduce Aβ 
production (Sonkusare et al., 2005; Nordberg, 
2006; Saxena et al., 2008). Consistent with 
the previous reports, the protective effects of 
AS605240 treated at 25 mg/kg were compa-
rable to those of donepezil on learning and 
memory impairments, as well as antioxidant 
capacities. Earlier reports indicated that 
AS605240 useful in general cognitive en-
hancement on the basis of its ability to im-
prove learning and memory in mice induced 
by β-amyloid 1-40 peptide (Passos et al., 
2010). AS605240 has also been suggested to 
improve the neurological function score, re-
duce the infarct size and decrease astrocyte 
activation in the stroke-related injury in the 
mouse model of transient intraluminal middle 
cerebral artery occlusion thereby aiding in the 
repair and remodeling of neurons (Shang et 
al., 2019). Further, AS605240 was reported to 
attenuate tissue-type plasminogen activator-
induced brain hemorrhage and improved mi-
crovascular patency after embolic stroke in 
rats likely contributing to the neuroprotective 
effect of AS605240 (Jin et al., 2019). Based 
on the above literature and the present data, 
our study supports the notion that the PI3K in-
hibitor, AS605240 can be considered as a 
neuroprotective therapeutic target in the treat-
ment of AD. However, the detailed neuropro-
tective mechanism that mediates the interplay 
between the inhibition of PI3Kγ and the pro-
tective outcome of AS605240 against ICV-
STZ-induced sporadic AD needs further in-
vestigation. 
In conclusion, our study demonstrated 
that AS605240 has protective effect against 
ICV-STZ-induced behavioral and biochemi-
cal parameters in rats. AS605240 administra-
tion to ICV-STZ induced sporadic AD rat im-
proves memory by its potential PI3K inhibi-
tion and antioxidative defense mechanisms 
proving its therapeutic potential in the treat-
ment and management of sporadic AD. 
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